Cancer research is a dynamic field constantly seeking innovative compounds that can offer new avenues for treatment. NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of supplying these essential research tools, including 2,2'-Cyclouridine (CAS: 3736-77-4), a compound that has shown significant promise in anticancer studies. Its unique ability to target specific enzymatic pathways makes it a valuable asset for oncological research and drug development.

The core of 2,2'-Cyclouridine's anticancer activity lies in its function as a uridine phosphorylase inhibitor. Uridine phosphorylase is an enzyme that plays a role in nucleotide metabolism, and its overactivity has been observed in certain types of cancer, contributing to tumor growth and resistance to chemotherapy. By inhibiting this enzyme, 2,2'-Cyclouridine can effectively starve cancer cells of essential metabolites, thereby hindering their proliferation and potentially inducing apoptosis. This specific anticancer mechanism makes it a compelling subject for further investigation.

Researchers looking to explore the 2,2'-Cyclouridine anticancer mechanism can rely on NINGBO INNO PHARMCHEM CO.,LTD. for high-purity compounds. Understanding the precise CAS 3736-77-4 chemical properties is crucial for designing effective experimental protocols. The compound's stability and solubility characteristics, when properly understood, allow for its optimal use in cell culture studies and in vivo models. This attention to detail ensures that the data generated contributes meaningfully to the advancement of cancer therapies.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting the scientific community in their efforts to develop new cancer treatments. By providing access to 2,2'-Cyclouridine, we empower researchers to investigate its therapeutic potential, refine drug delivery systems, and explore combination therapies. The ongoing research into this compound's capabilities underscores its importance as a key player in the fight against cancer.